{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T16:51:08Z","timestamp":1789750268457,"version":"4.0.1"},"reference-count":16,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2021,6,29]]},"DOI":"10.7759\/cureus.16035","type":"journal-article","created":{"date-parts":[[2021,6,29]],"date-time":"2021-06-29T21:17:07Z","timestamp":1625001427000},"source":"Crossref","is-referenced-by-count":10,"title":["Immune Checkpoint Inhibitor-Associated Thrombotic Thrombocytopenic Purpura in a Patient With Metastatic Non-Small-Cell Lung Cancer"],"prefix":"10.7759","author":[{"given":"Samantha","family":"De Filippis","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Colton","family":"Moore","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristin","family":"Ezell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kunal","family":"Aggarwal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amar H","family":"Kelkar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-14-1187","article-title":"Cancer immunotherapy: a future paradigm shift in the treatment of non-small cell lung cancer","volume":"21","author":"Anagnostou VK","year":"2015","unstructured":"Anagnostou VK, Brahmer JR. Cancer immunotherapy: a future paradigm shift in the treatment of non-small cell lung cancer. Clin Cancer Res. 2015, 21:976-84. 10.1158\/1078-0432.CCR-14-1187","journal-title":"Clin Cancer Res"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1038\/s41572-020-0160-6","article-title":"Immune-related adverse events of checkpoint inhibitors","volume":"6","author":"Ramos-Casals M","year":"2020","unstructured":"Ramos-Casals M, Brahmer JR, Callahan MK, et al.. Immune-related adverse events of checkpoint inhibitors. Nat Rev Dis Primers. 2020, 6:38. 10.1038\/s41572-020-0160-6","journal-title":"Nat Rev Dis Primers"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2017.00049","article-title":"Current diagnosis and management of immune related adverse events (IRAES) induced by immune checkpoint inhibitor therapy","volume":"8","author":"Kumar V","year":"2017","unstructured":"Kumar V, Chaudhary N, Garg M, Floudas CS, Soni P, Chandra AB. Current diagnosis and management of immune related adverse events (IRAES) induced by immune checkpoint inhibitor therapy. Front Pharmacol. 2017, 8:49. 10.3389\/fphar.2017.00049","journal-title":"Front Pharmacol"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2020.00091","article-title":"Potential immune-related adverse events associated with monotherapy and combination therapy of ipilimumab, nivolumab, and pembrolizumab for advanced melanoma: a systematic review and meta-analysis","volume":"10","author":"Almutairi AR","year":"2020","unstructured":"Almutairi AR, McBride A, Slack M, Erstad BL, Abraham I. Potential immune-related adverse events associated with monotherapy and combination therapy of ipilimumab, nivolumab, and pembrolizumab for advanced melanoma: a systematic review and meta-analysis. Front Oncol. 2020, 10:91. 10.3389\/fonc.2020.00091","journal-title":"Front Oncol"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1177\/1078155219887212","article-title":"Pembrolizumab-induced thrombotic thrombocytopenic purpura","volume":"26","author":"Dickey MS","year":"2020","unstructured":"Dickey MS, Raina AJ, Gilbar PJ, Wisniowski BL, Collins JT, Karki B, Nguyen AD. Pembrolizumab-induced thrombotic thrombocytopenic purpura. J Oncol Pharm Pract. 2020, 26:1237-40. 10.1177\/1078155219887212","journal-title":"J Oncol Pharm Pract"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1155\/2018\/2464619","article-title":"Thrombotic thrombocytopenic purpura due to checkpoint inhibitors","volume":"2018","author":"Youssef A","year":"2018","unstructured":"Youssef A, Kasso N, Torloni AS, Stanek M, Dragovich T, Gimbel M, Mahmoud F. Thrombotic thrombocytopenic purpura due to checkpoint inhibitors. Case Rep Hematol. 2018, 2018:2464619. 10.1155\/2018\/2464619","journal-title":"Case Rep Hematol"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1007\/s13730-020-00454-0","article-title":"Thrombotic thrombocytopenic purpura associated to dual checkpoint inhibitor therapy for metastatic melanoma","volume":"9","author":"Lafranchi A","year":"2020","unstructured":"Lafranchi A, Springe D, Rupp A, Ebn\u00f6ther L, Zschiedrich S. Thrombotic thrombocytopenic purpura associated to dual checkpoint inhibitor therapy for metastatic melanoma. CEN Case Rep. 2020, 9:289-90. 10.1007\/s13730-020-00454-0","journal-title":"CEN Case Rep"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.11246","article-title":"Thrombotic thrombocytopenic purpura induced by immune checkpoint inhibitiors: a case report and review of the literature","volume":"12","author":"Ali Z","year":"2020","unstructured":"Ali Z, Zafar MU, Wolfe Z, Akbar F, Lash B. Thrombotic thrombocytopenic purpura induced by immune checkpoint inhibitiors: a case report and review of the literature. Cureus. 2020, 12:e11246. 10.7759\/cureus.11246","journal-title":"Cureus"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1111\/trf.16117","article-title":"Refractory thrombotic thrombocytopenic purpura related to checkpoint inhibitor immunotherapy","volume":"61","author":"Lancelot M","year":"2021","unstructured":"Lancelot M, Miller MJ, Roback J, Stowell SR. Refractory thrombotic thrombocytopenic purpura related to checkpoint inhibitor immunotherapy. Transfusion. 2021, 61:322-8. 10.1111\/trf.16117","journal-title":"Transfusion"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1186\/s40425-017-0224-7","article-title":"Ipilimumab-induced thrombotic thrombocytopenic purpura (TTP)","volume":"5","author":"King J","year":"2017","unstructured":"King J, de la Cruz J, Lutzky J. Ipilimumab-induced thrombotic thrombocytopenic purpura (TTP). J Immunother Cancer. 2017, 5:19. 10.1186\/s40425-017-0224-7","journal-title":"J Immunother Cancer"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2019003810","article-title":"How I treat microangiopathic hemolytic anemia in patients with cancer","volume":"137","author":"Thomas MR","year":"2021","unstructured":"Thomas MR, Scully M. How I treat microangiopathic hemolytic anemia in patients with cancer. Blood. 2021, 137:1310-7. 10.1182\/blood.2019003810","journal-title":"Blood"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0609.2010.01448.x","article-title":"Cancer-associated microangiopathic hemolytic anemia with thrombocytopenia: an important diagnostic consideration","volume":"85","author":"Elliott MA","year":"2010","unstructured":"Elliott MA, Letendre L, Gastineau DA, Winters JL, Pruthi RK, Heit JA. Cancer-associated microangiopathic hemolytic anemia with thrombocytopenia: an important diagnostic consideration. Eur J Haematol. 2010, 85:43-50. 10.1111\/j.1600-0609.2010.01448.x","journal-title":"Eur J Haematol"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2016-10-709857","article-title":"Thrombotic thrombocytopenic purpura","volume":"129","author":"Joly BS","year":"2017","unstructured":"Joly BS, Coppo P, Veyradier A. Thrombotic thrombocytopenic purpura. Blood. 2017, 129:2836-46. 10.1182\/blood-2016-10-709857","journal-title":"Blood"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1038\/clpt.1981.154","article-title":"A method for estimating the probability of adverse drug reactions","volume":"30","author":"Naranjo CA","year":"1981","unstructured":"Naranjo CA, Busto U, Sellers EM, et al.. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther. 1981, 30:239-45. 10.1038\/clpt.1981.154","journal-title":"Clin Pharmacol Ther"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1186\/s41100-020-00278-9","article-title":"Pembrolizumab-associated thrombotic microangiopathy in a patient with urothelial cancer: a case report and literature review","volume":"6","author":"Hayata M","year":"2020","unstructured":"Hayata M, Shimanuki M, Ko T, et al.. Pembrolizumab-associated thrombotic microangiopathy in a patient with urothelial cancer: a case report and literature review. Renal Replacement Therapy. 2020, 6:29. 10.1186\/s41100-020-00278-9","journal-title":"Renal Replacement Therapy"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2020006052","article-title":"Cost effectiveness of caplacizumab in acquired thrombotic thrombocytopenic purpura","volume":"137","author":"Goshua G","year":"2021","unstructured":"Goshua G, Sinha P, Hendrickson JE, Tormey C, Bendapudi PK, Lee AI. Cost effectiveness of caplacizumab in acquired thrombotic thrombocytopenic purpura. Blood. 2021, 137:969-76. 10.1182\/blood.2020006052","journal-title":"Blood"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/63051-immune-checkpoint-inhibitor-associated-thrombotic-thrombocytopenic-purpura-in-a-patient-with-metastatic-non-small-cell-lung-cancer","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,9]],"date-time":"2024-02-09T19:31:18Z","timestamp":1707507078000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/63051-immune-checkpoint-inhibitor-associated-thrombotic-thrombocytopenic-purpura-in-a-patient-with-metastatic-non-small-cell-lung-cancer"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,6,29]]},"references-count":16,"URL":"https:\/\/doi.org\/10.7759\/cureus.16035","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2021,6,29]]}}}